Spartan Bioscience, a privately held molecular diagnostics company, has entered into an exclusive distribution agreement with Alere, a subsidiary of Alere Inc, for distribution of the Spartan RX CYP2C19 in Germany, Austria and Switzerland.
The Spartan RX CYP2C19 is a point-of-care, sample-to-result DNA testing system that helps cardiologists identify patients who carry the CYP2C19*2 gene mutation that causes impaired metabolism to the popular anti-blood clotting medication Plavix (clopidogrel).
Spartan Bioscience CEO Larry Andrea said they are pleased to have Alere as their exclusive distributor in Germany, Austria and Switzerland and their customer relationships and demonstrated expertise in this market will help expedite access to our products.
"Cardiologists have a need for the critical information that is provided by the Spartan CYP2C19 and we are enthusiastic about Alere’s ability to bring our value to hospitals and medical centers," Andrea said.
Alere managing director Dave Sieber said they have already experienced significant interest in the Spartan RX CYP2C19, and we are delighted to add the system to our portfolio of products.
"The Spartan RX CYP2C19 is an excellent fit with our expertise in the cardiology market, and we look forward to a long and prosperous partnership with Spartan," Sieber said.